News
![5 Things You'll Want to Watch With AbbVie's Q3 Results](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
5 Things You'll Want to Watch With AbbVie's Q3 Results
If 2017 ended right now, it would go down as AbbVie's (NYSE: ABBV) best ever. The biotech stock's price has risen a little more than the 50% gains AbbVie made during its first year as a....
![Price Hikes Insulate Celgene From a Failure](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Price Hikes Insulate Celgene From a Failure
After independent monitors concluded a phase 3 trial of GED-301 in Crohn's disease was a failure, Celgene (NASDAQ: CELG) shelved its plans to develop this drug for use in that billion-dollar....
![What's Behind Amgen's Q3 Revenue Decline](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
What's Behind Amgen's Q3 Revenue Decline
When Amgen (NASDAQ: AMGN) announced its second-quarter results in July, the anemic revenue growth was overshadowed by the company's solid earnings increase and its improved full-year guidance. CEO....
![Why MacroGenics, Inc. Stock Soared Today](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Why MacroGenics, Inc. Stock Soared Today
Shares of the clinical-stage oncology and autoimmune disease specialist MacroGenics (NASDAQ: MGNX) ended the day higher by a healthy 17.36% on a whopping 17.5 times the average volume.The....
![Why Did Innoviva, Inc. Stock Fall Nearly 16% Wednesday?](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Why Did Innoviva, Inc. Stock Fall Nearly 16% Wednesday?
Shares of bio-pharmaceutical company Innoviva (NASDAQ: INVA) fell as much as 17.4% on Wednesday. But the stock finished the trading day down 15.55%.The stock's decline came just before Innoviva....
![Biogen Inc Content With "Resilience" of Its Multiple Sclerosis Franchise](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Biogen Inc Content With "Resilience" of Its Multiple Sclerosis Franchise
Biogen (NASDAQ: BIIB) grew earnings faster than revenue in the third quarter, which is what investors should be looking for from any mature company in their portfolio. Nevertheless, shares went....
![This Marijuana Stock, With Its Eggs in 1 Basket, Popped 14% Last Week](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
This Marijuana Stock, With Its Eggs in 1 Basket, Popped 14% Last Week
When it comes to the markets' fastest growing industries, investors would have a hard time finding a group of stocks growing quicker than marijuana. According to a report from Marijuana Business....
![1 Small-Cap Biotech Stock to Buy Right Now](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
1 Small-Cap Biotech Stock to Buy Right Now
Enzymes. You may not realize it, but they're pretty important to daily life. Your high-efficiency, phosphate-free laundry detergent that removes even the most stubborn stains in cold water? That's....
![Better Buy: Johnson & Johnson vs. Pfizer](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Better Buy: Johnson & Johnson vs. Pfizer
They're two of the oldest, largest, and most respected healthcare companies around. But one has made investors much happier than the other in recent years. Johnson & Johnson (NYSE: JNJ) stock....
![Is Pfizer Inc. a Buy?](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Is Pfizer Inc. a Buy?
Pfizer Inc. (NYSE: PFE) shares have risen around 12% this year, in step with the iShares US Pharmaceuticals index. With talk of another spinoff and strong sales growth, this big pharma stock looks....
![Ionis Pharmaceuticals Tumbles on Biogen's Miss: Buy or Sell?](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Ionis Pharmaceuticals Tumbles on Biogen's Miss: Buy or Sell?
Ionis Pharmaceuticals (NASDAQ: IONS) lost 11% of its market value after commercialization partner Biogen (NASDAQ: BIIB) reported third-quarter sales of its drug, Spinraza, that failed to match....
![3 Value Stocks for Retirement](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
3 Value Stocks for Retirement
Retirement marks the crowning achievement of a lifetime of hard work and frugal saving. However, it does not mark the end of a marathon, as many believe. It merely marks the beginning of what will....
![Why Ionis Pharmaceuticals Inc. Slipped This Morning](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Why Ionis Pharmaceuticals Inc. Slipped This Morning
Shares of Ionis Pharmaceuticals Inc. (NASDAQ: IONS) dipped 13% lower in early morning trading on Tuesday after its most important collaboration partner reported some disturbing third-quarter sales....
![Is Regeneron Pharmaceuticals, Inc. Stock a Buy?](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Is Regeneron Pharmaceuticals, Inc. Stock a Buy?
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stock has been a huge winner in the past. A $10,000 investment in the biotech 10 years ago would be worth more than $200,000 today. Regeneron's....
![3 Top Biotech Stocks to Buy Now](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
3 Top Biotech Stocks to Buy Now
You should seriously consider adding a few biotech stocks to your portfolio if you don't already own some. Why? Because they give you an opportunity to make higher returns.And the good news is....
![In Case You Missed It, Johnson & Johnson Is Undergoing a Major Business Transformation](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
In Case You Missed It, Johnson & Johnson Is Undergoing a Major Business Transformation
Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) is what you might call a staple stock. It's a common holding for growth, value, and income investors given that many of the products it....
![Better Buy: Gilead Sciences, Inc. vs. Amgen](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Better Buy: Gilead Sciences, Inc. vs. Amgen
Amgen (NASDAQ: AMGN) and Gilead Sciences (NASDAQ: GILD) are central figures within the biotech landscape. However, these two titans of the industry are both in the process of refreshing their....
![3 Small, Profitable Biotechs With Fantastic Growth](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
3 Small, Profitable Biotechs With Fantastic Growth
Investors could be forgiven for shying away from the stocks of small biotechs. Not only is the complex technology behind their products almost impossible for most of us to understand, the majority....
![Is This $13 Billion Food Security Crisis Intrexon's Next Big Opportunity?](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Is This $13 Billion Food Security Crisis Intrexon's Next Big Opportunity?
A few years ago, engineered biology conglomerate Intrexon (NYSE: XON) acquired a pioneering company called Oxitec. While there are plenty of whacky technology platforms in next-generation biotech,....
![Why Exactech Skyrocketed 31% Today](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Why Exactech Skyrocketed 31% Today
After agreeing to be taken private by global alternative asset manager TPG Capital, Exactech (NASDAQ: EXAC) jumped 31% today.Exactech makes orthopedic implant devices and related surgical....
![Fintech Joint Venture Launched: Here's Why Investors Should Take Notice](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Fintech Joint Venture Launched: Here's Why Investors Should Take Notice
As the fintech industry matures, more and more companies in this arena are looking to either encroach on traditional banks' territory or figure out ways they can service banks to help usher them....
![Why DBV Technologies SA Plummeted and Aimmune Therapeutics Inc Skyrocketed Today](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Why DBV Technologies SA Plummeted and Aimmune Therapeutics Inc Skyrocketed Today
DBV Technologies (NASDAQ: DBVT) is down 45% at 12:48 p.m. EDT after announcing that its peanut allergy treatment, Viaskin Peanut, failed -- albeit not by much -- a phase 3 trial. The results....
![Why Agenus Inc. Stock Briefly Popped Today](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Why Agenus Inc. Stock Briefly Popped Today
Agenus (NASDAQ: AGEN), a clinical-stage cancer immunotherapy company, saw its shares open up 13% higher Monday on trading volumes nearly six times the daily average. The move came in response to....
![A Foolish Take: The Best-Performing S&P 500 Stock This Year](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
A Foolish Take: The Best-Performing S&P 500 Stock This Year
It has been a good year so far for stocks, with the S&P 500 up 15% since the beginning of 2017. But that's just an average of the 500 stocks on the large-cap index; some have done even....
![3 Gene Therapy Stocks That Could Make You Rich](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
3 Gene Therapy Stocks That Could Make You Rich
The FDA just approved another gene-altering cancer treatment that will save thousands of lives. Yescarta from Gilead Sciences (NASDAQ: GILD) teaches cancer patients' immune cells to seek out and....